Reports

Drug name	NICE TAs	Comments
Vamorolone (Agamree®)	NICE TA 1031 Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
Vanzacaftor / tezacaftor / deutivacaftor (Alyftrek®)	NICE TA 1085 Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
Varenicline (Champix®)	TA123 - Varenicline for smoking cessation
Vedolizumab	TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis TA352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	Hospital only - use in line with NICE Off label use - for the treatment of refractory immunotherapy-related colitis
Vemurafenib tablets	TA269 - Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	National CDF list
Venetoclax (Venclyxto®)	TA487 - Venetoclax for treating chronic lymphocytic leukaemia TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia TA796: Venetoclax for treating chronic lymphocytic leukaemia	For hospital use only And azacitidine for relapsed or refractory AML
Verteprofin (Visudyne)	TA68 - Guidance on the use of photodynamic therapy for age-related macular degeneration
Vibegron	NICE TA 999 Vibegron for treating symptoms of overactive bladder syndrome
Vinflunine	TA272 - Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	Negative TA
Vortioxetine (Brintellix)	TA367 - Vortioxetine for treating major depressive episodes	Specialist initiation only and RICaD

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports